Literature DB >> 12039649

Glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats and the response to hormones.

Cristiane Vicentino1, Jorgete Constantin, Luciano Aparecido Stecanella, Adelar Bracht, Nair S. Yamamoto.   

Abstract

The alterations in hepatic glucose and glycogen catabolism were evaluated in rats bearing the Walker-256 tumor. Food intake was monitored concomitantly with measurements of the in vivo hepatic glycogen levels. Glycogenolysis, glycolysis and oxygen uptake were measured in the isolated perfused liver. The hepatic glucose phosphorylating capacity was measured in the high-speed supernatant fraction of liver homogenates. Food intake was 21.4% reduced in tumor-bearing rats; the glycogen levels were decreased by 63.6%. Initial basal rates of glucose release (glycogenolysis) and lactate+pyruvate production from endogenous glycogen (glycolysis) in the perfused liver were not changed by the tumor-bearing state, resulting in a higher relative rate of glycogen breakdown (% of glycogen degradation per unit time). In absolute terms stimulation of glycogen mobilization by glucagon or norepinephrine was smaller in the tumor-bearing state. The percentage of extra glycogen degradation per unit time caused by both hormones, however, was practically the same in the control and in the tumor-bearing state. The hepatic glucose phosphorylating capacity was reduced from 3.92+/-0.39 nmolmin(-1)(mgprotein)(-1) in normal rats to 2.61+/-0.23 nmolmin(-1)(mgprotein)(-1) in livers from tumor-bearing rats. Glycolysis from exogenous glucose (20 mM) in perfused livers was diminished from 0.136+/-0.023 &mgr;molmin(-1)(gliver)(-1) in normal rats to 0.046+/-0.008 &mgr;molmin(-1)(gliver)(-1) in tumor-bearing rats. It can be concluded that livers from rats bearing the Walker-256 tumor are less able to transform glucose and accumulate glycogen while possessing a greater tendency of releasing glucose from the glycogen stores.

Entities:  

Year:  2002        PMID: 12039649     DOI: 10.1016/s0928-4680(02)00003-2

Source DB:  PubMed          Journal:  Pathophysiology        ISSN: 0928-4680


  3 in total

1.  Decreased response to cAMP in the glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats.

Authors:  Hely de Morais; Priscila Cassola; Carolina Campos Lima Moreira; Suéllen Kathiane Fernandes Vilas Bôas; Glaucia Regina Borba-Murad; Roberto Barbosa Bazotte; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2012-05-26       Impact factor: 3.396

2.  Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.

Authors:  Camila Oliveira de Souza; Mirian Ayumi Kurauti; Flaviane de Fatima Silva; Hely de Morais; Glaucia Regina Borba-Murad; Fábio Goulart de Andrade; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2014-10-31       Impact factor: 3.396

3.  The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats.

Authors:  Nan Li; Bin Chen; Run Lin; Ni Liu; Hai-Tao Dai; Ke-Yu Tang; Jian-Yong Yang; Yong-Hui Huang
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-01       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.